14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
SIGA vs ETON: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin), whereas ETON carries 34.0/100 (SELL) at $61.36 (18.6x Forward P/E, 31.3% operating margin).
Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. ETON 34.0/100 SELL), ETON captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (31.3% vs. -14.2% operating margin) and revenue trajectory (+157.9% vs. -49.7% YoY).
Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile ETON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 57.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $187.9M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment37.6% of Rev ($20M)
90D Engineering Disclosures0 Published
ETON Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.8B market capitalization and 31.3% operating margin.
OpEx & R&D Reinvestment39.9% of Rev ($56M)
90D Engineering Disclosures0 Published
Investor FAQ SIGA vs ETON Key Questions & Quantitative Answers
As of Nov 19, 2026, Eton Pharmaceutcials, Inc. (ETON) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SIGA carries a Unified Composite Score of 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin), whereas ETON carries 34.0/100 (SELL) at $61.36 (18.6x Forward P/E, 31.3% operating margin). Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. ETON 34.0/100 SELL), ETON captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (31.3% vs. -14.2% operating margin) and revenue trajectory (+157.9% vs. -49.7% YoY). Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile ETON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 57.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ETON leads the Growth & Scale pillar: SIGA posts -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin), compared with ETON at +157.9% YoY revenue growth and -12.6% YoY earnings growth on $141M TTM revenue (71.2% gross margin, 31.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SIGA cumulative revenue shifted -81.2% while ETON shifted +300.0%. In operating R&D and SG&A reinvestment, SIGA deploys 37.6% of Rev ($20M) (0 90-day corporate R&D disclosures) versus 39.9% of Rev ($56M) (0 disclosures) for ETON.
SIGA screens cheaper on headline valuation multiples. SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin), whereas ETON trades at 18.6x Forward P/E, 41.3x Trailing P/E, N/M PEG, and 12.5x EV/Revenue (14.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIGA (0.4% ROE) versus ETON (90.6% ROE) capital efficiency.
In options market volatility and institutional positioning, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk). By comparison, ETON carries 99.5% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.71β · 98% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.